303 related articles for article (PubMed ID: 24180329)
21. Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Zohren F; Bruns I; Pechtel S; Schroeder T; Fenk R; Czibere A; Maschmeyer G; Kofahl-Krause D; Niederle N; Heil G; Losem C; Welslau M; Brugger W; Germing U; Kronenwett R; Barth J; Rummel MJ; Haas R; Kobbe G
Blood; 2015 Sep; 126(12):1407-14. PubMed ID: 26239087
[TBL] [Abstract][Full Text] [Related]
22. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
23. Impact of age on clinical risk scores in follicular lymphoma.
Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
[TBL] [Abstract][Full Text] [Related]
24. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.
Takahashi H; Tomita N; Sakata S; Tsuyama N; Hashimoto C; Ohshima R; Matsuura S; Ogawa K; Yamamoto W; Kameda Y; Enaka M; Inayama Y; Kasahara M; Takekawa Y; Onoda N; Motomura S; Ishigatsubo Y; Takeuchi K
Eur J Haematol; 2013 Apr; 90(4):286-90. PubMed ID: 23331211
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
[TBL] [Abstract][Full Text] [Related]
29. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
[TBL] [Abstract][Full Text] [Related]
30. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M
Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296
[TBL] [Abstract][Full Text] [Related]
31. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
32. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
33. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
Zhou Y; Qin Y; He X; Liu P; Yang J; Zhou L; Zhou S; Gui L; Yang S; Zhang C; Shi Y
Asia Pac J Clin Oncol; 2021 Jun; 17(3):289-299. PubMed ID: 32970914
[TBL] [Abstract][Full Text] [Related]
35. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
[TBL] [Abstract][Full Text] [Related]
37. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
39. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
40. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
